The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis

Platelets

Volumn 24, Issue 7, 2013, Pages 503-515

  Pauling, J D ^a   O'donnell, V B ^b   Mchugh, N J ^a,c  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c University of Bath   (United Kingdom)

Author keywords

Inflammation; Pathogenesis; Platelets; Raynaud's; Scleroderma; Systemic Sclerosis

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 [2 (2 CHLOROPHENYL) 4 (2 HYDROXYPHENYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; ACETYLSALICYLIC ACID; DAZMEGREL; DAZOXIBEN; DIPYRIDAMOLE; LOSARTAN; PICOTAMIDE; PLACEBO; TICLOPIDINE;

ANGIOGENESIS; AUTOIMMUNITY; CHEMOTAXIS; FIBROSIS; GRANULE CELL; HEMOSTASIS; IMMUNOCOMPETENT CELL; INFLAMMATION; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; WOUND HEALING;

ANIMALS; BLOOD PLATELETS; HUMANS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 84884799138     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.719090     Document Type: Review

References (121)

1. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005;44(5):587-596
2. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347(13):1001-1008
3. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22(4):675-694
4. Varga J, Denton CP, Wigley FM. editor. Scleroderma: From pathogenesis to comprehensive management. New York: Springer, 2012
5. Ribatti D, Crivellato E. Giulio Bizzozero and the discovery of platelets. Leuk Res 2007;31(10):1339-1341
6. Klinger MH. Platelets and inflammation. Anat Embryol (Berl) 1997;196(1):1-11
7. Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets 2007;18(5):319-328
8. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;99(5):938-945
9. O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med 2006;173(5):483-490
10. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3(7):425-430
11. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003;1(9):1897-1905
12. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19(6):574-579
13. Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981;78(7):4584-4587
14. Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: Does it exist? Am J Hematol 2002;70(2):139-144
15. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391(6667):591-594
16. Chen MC, Chang HW, Wu CJ, Yang CH, Hung WC, Yeh KH, Fu M. Percutaneous transluminal mitral valvuloplasty reduces circulating soluble CD40 ligand in rheumatic mitral stenosis. Chest 2005;128(1):36-41
17. Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol 1998;10(6):435-442
18. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogné M, Richard Y, Garraud O. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 2007;35(9):1376-1387
19. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98(4):1047-1054
20. Lev PR, Salim JP, Marta RF, Osorio MJ, Goette NP, Molinas FC. Platelets possess functional TGF-beta receptors and Smad2 protein. Platelets 2007;18(1):35-42
21. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011;10(10):590-594
22. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008;47(Suppl. 5):v2-v4
23. Matsumura Y, Murata S, Takada K, Takaoka M, Morimoto S. Involvement of transforming growth factor-beta 1 for plateletsinduced stimulation of endothelin-1 production. Clin Exp Pharmacol Physiol 1994;21(12):991-996
24. Frayha RA, Shulman LE, Stevens MB. Hematological abnormalities in scleroderma. A study of 180 cases. Acta Haematol 1980;64(1):25-30
25. Price JE, Klimiuk PS, Jayson MI. In vitro platelet aggregability studies: Lack of evidence for platelet hyperactivity in systemic sclerosis. Ann Rheum Dis 1991;50(8):567-571
26. Shemirani AH, Nagy Jr. B, Takáts AT, Zsóri KS, András C, Kappelmayer J, Csiki Z. Increased mean platelet volume in primary Raynaud's phenomenon. Platelets 2012;23(4):312-316
27. Hutton RA, Mikhailidis DP, Bernstein RM, Jeremy JY, Hughes GR, Dandona P. Assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol 1984;37(2):182-187
28. Wilkinson D, Vowden P, Gilks L, Latif AB, Rajah SM, Kester RC. Plasma eicosanoids, platelet function and cold sensitivity. Br J Surg 1989;76(4):401-405
29. Cuenca R, Fernández-Cortijo J, Lima J, Fonollosa V, Simeón CP, Pico M, Soriano B, Vilardell M. Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma. Med Clin (Barc) 1990;95(20): 761-763
30. Lau CS, McLaren M, Saniabadi A, Belch JJ. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993;22(3):97-101
31. Goodfield MJ, Orchard MA, Rowell NR. Increased platelet sensitivity to collagen-induced aggregation in whole blood patients with systemic sclerosis. Clin Exp Rheumatol 1988;6(3):285-288
32. Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993;84(4):675-680
33. Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther 2008;10(5):R103
34. Biondi ML, Marasini B. Abnormal platelet aggregation in patients with Raynaud's phenomenon. J Clin Pathol 1989;42(7):716-718
35. Reilly IA, Roy L, Fitzgerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J (Clin Res Ed) 1986;292(6527):1037-1039
36. Belch JJ, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985;24(4):346-350
37. Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. Clin Exp Rheumatol 1984;2(2):119-123
38. Dowie A, Francis JL, Roath OS, Challenor VF, Waller DG. Platelet aggregation in primary Raynaud's phenomenon and the effect of Enalapril administration. Platelets 1990;1(1):25-27
39. Seibold JR, Harris JN. Plasma beta-Thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J Rheumatol 1985;12(1):99-103
40. Lima J, Fonollosa V, Fernández-Cortijo J, Ordi J, Cuenca R, Khamashta MA, Vilardell M, Simeón CP, Picó M. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991;18(12):1833-1836
41. Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002;29(12):2565-2570
42. Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-Thromboglobulin in scleroderma. Ann Intern Med 1982;96(5):610-613
43. Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR, Moult J, Holt CM, Lindsey N, Hughes P. Anticardiolipin antibodies in systemic sclerosis: Immunological and clinical associations. Clin Exp Immunol 1988;73(3): 456-460
44. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, beta-Thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55(2):122-127
45. Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005;64(3):484-486
46. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94(4 pt. 1):482-484
47. Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20(8):1325-1330
48. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995;34(9):814-819
49. Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, Khamashta MA, Hughes GR, Brancaccio V. The coagulation/ fibrinolysis balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br J Rheumatol 1997;36(10):1045-1050
50. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-Associated pulmonary arterial hypertension. Ann Rheum Dis 2008;67(8):1121-1126
51. Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88(8):914-918
52. Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G, Fenu L, Generini S, Cinotti S, Morfini M, Pignone A, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003;32(5): 285-295
53. Mannucci PM, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989;73(6):1586-1591
54. Matucci-Cerinic M, Pignone A, Iannone F, Lotti T, Pesciullesi E, Spillantini G, Falcini F, Cagnoni M. Clinical correlations of plasma Angiotensin Converting Enzyme (ACE) activity in systemic sclerosis: A longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 1990; 84(4):283-287
55. Scheja A, Eskilsson J, Akesson A, Wollheim FA. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis. J Rheumatol 1994;21(4):639-642
56. Kumanovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008;26(3): 414-420
57. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-Type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11(4):375-382
58. Marasini B, Casari S, Bestetti A, Maioli C, Cugno M, Zeni S, Turri O, Guagnellini E, Biondi ML. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J Rheumatol 2000;27(11):2621-2623
59. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995;22(10):1876-1883
60. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992;175(5):1227-1234
61. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009;36(3):576-582
62. Riccieri VSK, Vasile M, Macrì V, Sciarra I, Iannace N, Alessandri C, Valesin G. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 2011;29(2):s46-s52
63. Solanilla A, Villeneuve J, Auguste P, Hugues M, Alioum A, Lepreux S, Ducroix JP, Duhaut P, Conri C, Viallard JF, et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009;48(9):1036-1044
64. Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F, Cervini C. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001;30(5):290-296
65. Dunbar PR, Harrison A, Corkill MM, Neale TJ. Immunoassay of platelet-derived growth factor in the plasma of patients with scleroderma. Br J Rheumatol 1993;32(11):966-971
66. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15(6):772-777
67. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005;44(12):1518-1524
68. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE. Plasma TGF beta in systemic sclerosis: A crosssectional study. Ann Rheum Dis 1994;53(11):763-767
69. Doran JP, Veale DJ. Biomarkers in systemic sclerosis. Rheumatology (Oxford) 2008;47(Suppl. 5):v36-v38
70. Valentini G, Romano MF, Naclerio C, Bisogni R, Lamberti A, Turco MC, Venuta S. Increased expression of CD40 ligand in activated CD T lymphocytes of systemic sclerosis patients. J Autoimmun 2000;15(1):61-66
71. Kuwana M, Medsger Jr. TA, Wright TM. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995;155(5):2703-2714
72. Allanore Y, Borderie D, Meune C, Lemaréchal H, Weber S, Ekindjian OG, Kahan A. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005;64(3):481-483
73. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004;31(3):514-519
74. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: Relationship to organ systemic involvement. Clin Rheumatol 2005;24(2):111-116
75. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Brühlmann P, Müller-Ladner U, et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4(6):R11
76. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010;5(8):e12106
77. Kamath S, Blann AD, Lip GY. Platelet activation: Assessment and quantification. Eur Heart J 2001;22(17):1561-1571
78. Seibold Jr. Serotonin and Raynaud's phenomenon. J Cardiovasc Pharmacol 1985;7(Suppl. 7):S95-S98
79. Coffman JD, Cohen RA. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. Clin Sci (Lond) 1994;86(3):269-273
80. Biondi ML, Marasini B, Bianchi E, Agostoni A. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Int J Cardiol 1988;19(3):335-339
81. Klimiuk PS, Grennan A, Weinkove C, Jayson MI. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989;48(7):586-589
82. Olewicz-Gawlik A, Danczak-Pazdrowska A, Klama K, Silny W, Prokop J, Mackiewicz S, Grala P, Hrycaj P. Blood serum levels of amino-Terminal pro-C-Type natriuretic peptide in patients with systemic sclerosis. Connect Tissue Res 2010;51(2):83-87
83. Blann AD, Constans J, Carpentier P, Renard M, Satger B, Guérin V, Boisseau MR, Neau-Cransac N, Conri C. Soluble P selectin in systemic sclerosis: Relationship with von Willebrand factor, autoantibodies and diffuse or localised/limited disease. Thromb Res 2003;109(4):203-206
84. Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M. Circulating P-And L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 1999;18(1):28-32
85. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38(2):184-189
86. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61(5-6):239-246
87. Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: A comparative study. Blood Coagul Fibrinolysis 2007;18(4):297-302
88. Polidoro L, Barnabei R, Giorgini P, Petrazzi L, Ferri C, Properzi G. Platelet activation in patients with the Raynaud's Phenomenon. Intern Med J 2010;42(5):531-535
89. Sakamoto K, Houya I, Inoue K, Tanaka M, Suzuki T, Sakamoto Y, Matsuo H. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. Eur Respir J 1999;13(1):137-144
90. Young V, Ho M, Vosper H, Belch JJ, Palmer CN. Elevated expression of the genes encoding TNF-Alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology (Oxford) 2002;41(8):869-875
91. Oyabu C, Morinobu A, Sugiyama D, Saegusa J, Tanaka S, Morinobu S, Tsuji G, Kasagi S, Kawano S, Kumagai S. Plasma platelet-derived microparticles in patients with connective tissue diseases. J Rheumatol 2011;38(4):680-684
92. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jüngel A, Beyer C, Krönke G, Zwerina J, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208(5):961-972
93. Piguet PF, Vesin C. Pulmonary platelet trapping induced by bleomycin: Correlation with fibrosis and involvement of the beta 2 integrins. Int J Exp Pathol 1994;75(5):321-328
94. Piguet PF, Kaufman S, Barazzone C, Muller M, Ryffel B, Eugster HP. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol 1997;78(1): 43-48
95. Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008;67(6):867-872
96. Jones EW, Hawkey CJ. A thromboxane synthetase inhibitor in Raynaud's phenomenon. Prostaglandins Leukot Med 1983;12(1):67-71
97. Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, Prentice CR. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double-blind trial. Br J Clin Pharmacol 1983;15(Suppl. 1):113S-116S.
98. Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmacol Ther 1984;36(3):369-373
99. Luderer JR, Nicholas GG, Neumyer MM, Riley DL, Vary JE, Garcia G, Schneck DW. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clin Pharmacol Ther 1984;36(1):105-115
100. Rustin MH, Grimes SM, Kovacs IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P, Kirby JD. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. Eur J Clin Pharmacol 1984;27(1):61-65
101. Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, Chesebro JH, O'Fallon WM. Trial of plateletinhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984;27(10):1137-1143
102. Tindall H, Tooke JE, Menys VC, Martin MF, Davies JA. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Eur J Clin Invest 1985;15(1):20-23
103. Destors JM, Gauthier E, Lelong S, Boissel JP. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon. Angiology 1986;37(8):565-569
104. van der Meer J, Wouda AA, Kallenberg CG, Wesseling H. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. VASA Suppl 1987;18:71-75
105. Lau CS, Khan F, McLaren M, Bancroft A, Walker M, Belch JJ. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int 1991; 11(4-5):163-168
106. Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997;242(5):373-376
107. Easter MJ, Marshall JM. Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud's disease. Clin Sci (Lond) 2005;109(1):45-54
108. Tohgi H, Tamura K, Kimura B, Kimura M, Suzuki H. Individual variation in platelet aggregability and serum thromboxane B2 concentrations after low-dose aspirin. Stroke 1988;19(6):700-703
109. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest, 1979;63(3):532-535
110. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-To-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992;23(10):1400-1403
111. Moncada S. Adventures in vascular biology: A tale of two mediators. Philos Trans R Soc Lond B Biol Sci 2006;361(1469):735-759
112. Agache I, Radoi M, Duca L. Platelet activation in patients with systemic scleroderma-Pattern and significance. Rom J Intern Med 2007;45(2):183-191
113. Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008;28(3):s39-s42
114. Takehara K, Grotendorst GR, Silver R, LeRoy EC. Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis 1987;7(2):152-158
115. Takehara K, Igarashi A, Ishibashi Y. Dipyridamole specifically decreases platelet-derived growth factor release from platelets. Pharmacology 1990;40(3):150-156
116. McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, Black CM, Maddison PJ. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47(1):43-47
117. Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30(3):281-286
118. Malamet R, Wise RA, Ettinger WH, Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985;78(4):602-608
119. Moriau M, Lavenne-Pardonge E, Crasborn L, von Frenckell R, Col-Debeys C. Treatment of the Raynaud's phenomenon with piracetam. Arzneimittelforschung 1993;43(5):526-535
120. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001;40(9):1038-1043
121. Stucker O, Pons C, Duverger JP, Drieu K, D'Arbigny P. Effect of Ginkgo biloba extract (EGb 761) on the vasospastic response of mouse cutaneous arterioles to platelet activation. Int J Microcirc Clin Exp 1997;17(2):61-66